Citius Pharma announces, achieved significant milestones for Mino-Lok

▴ minolok-antibiotic-lock-solution-being-developed-adjunctive-therapy
Citius Pharmaceuticals achieves chemical manufacturing and control milestones for Mino-Lok

Citius Pharmaceuticals, Inc., a speciality pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok.

Mino-Lok is an antibiotic lock solution being developed as adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). Mino-Lok contains three active drug substances (minocycline, ethanol and EDTA) which are combined into two vials, MLT01 (minocycline) and MLT02 (ethanol and EDTA). Citius has manufactured three registration lots of Mino-Lok using the commercial manufacturing process, which will be filed in the planned New Drug Application (NDA). Citius has placed all registration lots on stability at the appropriate ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) conditions to support the NDA filing. Citius has also developed a new exclusive synthesis process for disodium edetate ("EDTA"), a chelating agent which supplants heparin as the anti-clotting agent in Mino-Lok.

NDAs are applications to request permission to market a drug product in the U.S. for a specific use. Chemistry, manufacturing, and controls (CMC) information is therefore submitted in the NDA to ensure product quality as it relates to the safety and efficacy of the drug product.

"A typical drug approval contains one drug substance, so for all practical purposes, our team has developed three products. Mino-Lok is unique in many ways, this being one of them," said Myron Holubiak, Chief Executive Officer of Citius. "It's important to know that we expect to be prepared to immediately move to validation/commercial manufacturing upon the completion of our Phase 3 clinical trial and receiving the required FDA clearance."

Citius is a late-stage speciality pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Tags : #CitiusPharmaceuticals #MyronHolubiak #NewDrugApplication #BloodstreamInfections

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-


Trending Now

Symptoms and tips for care while dealing with heart diseasesOctober 01, 2022
Natural Ways to Treat Baby Cold CoughOctober 01, 2022
Gall Bladder Stone Pain October 01, 2022
International Day For Older Persons 2022October 01, 2022
Uwal Healthcare can provide high quality generic medicines at 15 to 16% lower costOctober 01, 2022
8 Extremely deadly symptoms you Need to Know about Herpes Simplex VirusSeptember 30, 2022
8 Extremely deadly symptoms you Need to Know about Herpes Simplex VirusSeptember 30, 2022
Post-abortion diet for faster recovery – Foods to eat and to avoidSeptember 30, 2022
Post-abortion diet for faster recovery – Foods to eat and to avoidSeptember 30, 2022
Post-abortion diet for faster recovery – Foods to eat and to avoidSeptember 30, 2022
Resolute -A digital wellness platform providing Hyper-Personalised holistic solutionsSeptember 30, 2022
World Heart Day 2022 – Eat heart-healthy to keep your heart healthySeptember 29, 2022
Loneliness - A deadly cause of your depression you must knowSeptember 29, 2022
Loneliness - A deadly cause of your depression you must knowSeptember 29, 2022
Loneliness - A deadly cause of your depression you must knowSeptember 29, 2022
Know About PCOS Awareness Month-2022 September 29, 2022
What is long covid and how does it affect the body? September 29, 2022
Calcium is essential for smooth functioning of the body and good bone healthSeptember 28, 2022
World Rabies Day 2022 – Rabies symptoms and standard treatmentSeptember 28, 2022
Drinking Amla water gives health 8 tremendous benefitsSeptember 28, 2022